MARKET

ENTA

ENTA

Enanta Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

53.56
-1.29
-2.35%
Opening 15:27 01/27 EST
OPEN
53.91
PREV CLOSE
54.85
HIGH
54.33
LOW
53.34
VOLUME
107.10K
TURNOVER
--
52 WEEK HIGH
106.80
52 WEEK LOW
53.34
MARKET CAP
1.06B
P/E (TTM)
24.12
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ENTA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ENTA News

  • The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study
  • Benzinga.3d ago
  • Enanta to Host Conference Call on February 6 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2019
  • Business Wire.3d ago
  • The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment
  • Benzinga.4d ago
  • The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings
  • Benzinga.5d ago

More

Industry

Biotechnology & Medical Research
-0.93%
Pharmaceuticals & Medical Research
-0.35%

Hot Stocks

Name
Price
%Change

About ENTA

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
More

Webull offers Enanta Pharmaceuticals Inc (ENTA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.